ASH 2020: CAR T-Cell Therapy Updates | Supplements And Featured Publications

Liso-Cel Proves to Be Highly Active, Tolerable in Relapsed/Refractory MCL

December 17, 2020

December 17, 2020 - Lisocabtagene maraleucel exhibited promising antitumor activity with low rates of grade 3 or higher cytokine release syndrome and neurotoxicity in patients with relapsed/refractory mantle cell lymphoma.

Cilta-Cel Improves HRQoL in Relapsed/Refractory Multiple Myeloma

December 06, 2020

Ciltacabtagene autoleucel was found to elicit clinically meaningful improvements in health-related quality of life in patients with relapsed/refractory multiple myeloma, and this benefit may become even more pronounced as responses to treatment deepen over time, according to data from the CARTITUDE-1 study presented during the 2020 ASH Annual Meeting & Exposition.

Allogeneic Off-the-Shelf UCART22 Product Shows Early Activity, Tolerability in Relapsed/Refractory CD22+ B-Cell ALL

December 06, 2020

December 6, 2020 - UCART22, an allogeneic off-the-shelf CD22-directed T-cell product, showed no unexpected toxicities at 2 dose levels and had early signs of activity in adult patients with relapsed/refractory CD22-positive B-cell acute lymphoblastic leukemia.

Off-the-Shelf CAR Therapy Shows Early Promise in Multiple Myeloma

December 05, 2020

ALLO-715, an off-the-shelf chimeric antigen receptor T-cell therapy that targets B-cell maturation antigen, elicited responses in heavily pretreated patients with relapsed/refractory multiple myeloma in early findings from a first-in-human study presented at the 2020 ASH Meeting.

Axi-Cel Elicits Long-Term Disease Control in Large B-Cell Lymphoma

December 05, 2020

December 5, 2020 - The CAR T-cell therapy axicabtagene ciloleucel demonstrated long-term disease control with rapid responses and robust CAR T-cell expansion among patients with refractory large B-cell lymphoma.